Expression and significant roles of the long non-coding RNA CASC19/miR-491-5p/HMGA2 axis in the development of gastric cancer

Figure 1 The clinical and biological function of CASC19 in gastric cancer. A: The expression of CASC19 in cancer tissues and adjacent tissues of 72 gastric cancer patients were measured by reverse transcription polymerase chain reaction; B: The expression level of CASC19 in gastric cancer cell lines and GES-1 was measured; C: The transfection result of si-CASC19-1, si-CASC19-2, si-CASC19-3 into MGC803 cells and AGS cell lines; D: The K-M survival curve of high CASC19 group and low groups; E: The effect of si-CASC19-2 on cell proliferation was detected by cell counting kit-8; F: The effect of si-CASC19-2 on cell proliferation was detected by ethynyldeoxyuridine; G: The result of wound healing assay after inhibiting CASC19; H: The invasive ability of MGC803 and AGS cells after inhibiting CASC19 by transwell; I: The cell apoptosis result after knockdown of CASC19 by flow cytometry; J: The level of apoptosis-related proteins were detected by Western blot experiment; K: The level of epithelial-mesenchymal transition-related proteins was examined by western blot. ^aP < 0.05, ^bP < 0.01, ^cP < 0.001, ^eP < 0.01, ^fP < 0.001 was compared with the control group respectively. P < 0.05 was considered statistically significant.